J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29
J.P. Morgan has reiterated its Buy rating on Odyssey Therapeutics (ODTX.US) and increased its target price for the company's stock to $29. This adjustment reflects a continued positive outlook from the financial institution regarding Odyssey Therapeutics' future performance.